The biology of aging is real and well mapped. The clinical evidence for treating it with stem cells comes from a handful of trials, all in people who already had frailty, and the most recent one is the best.
What Aging Actually Is
The field has converged on describing aging as a set of interacting cellular processes — the "hallmarks of aging" [1].
Cellular senescence. Cells stop dividing but do not die, accumulating with age and secreting inflammatory signals [7]. In mice, clearing these cells extends healthy lifespan [8], and senolytic drugs improve physical function in old animals [9]. ⚠️ Both are mouse studies. They are why the field is interesting; they are not evidence about people.
Inflammaging. Chronic, low-grade, sterile inflammation that rises with age and tracks with age-related disease [10].
Stem cell exhaustion. The regenerative capacity of endogenous stem cell pools declines with age [11].
Epigenetic change. DNA methylation patterns shift with age regularly enough to build "epigenetic clocks" that estimate biological age [6].
⚠️ A clock that measures aging is not a treatment for aging. Epigenetic clocks are a measurement tool. No trial on this page — and none I could find — shows MSC therapy moving one.
What MSCs Are, and What They Do
Mesenchymal stromal cells act mainly by paracrine signalling — secreting factors that modulate inflammation and support tissue repair — rather than by engrafting and becoming new tissue [2][5].
⚠️ The name is contested by the person who coined it. Arnold Caplan has argued these should be renamed "medicinal signalling cells", because they do not meaningfully differentiate into new tissue in patients and calling them "stem cells" misleads [12]. That comes from the field's founder and belongs on any page using the term.
⚠️ They are not immune-privileged. Allogeneic MSCs are immune evasive, not immune privileged — a distinction that matters for repeat dosing [13].
On umbilical cord cells specifically: cord-derived MSCs do show higher proliferative capacity and a different secretory profile than adult marrow or adipose cells. ⚠️ Those are laboratory attributes. "Potency" in cell therapy is a defined regulatory term requiring a validated assay tied to mechanism of action, and no such assay is cited for any product described here. Faster proliferation in a flask is not a demonstrated clinical advantage in a person.
What the Trials Found
All of the trials below enrolled people who already had frailty. None enrolled healthy adults. That is the single most important thing to know when reading them.
Phase 1 — Golpanian 2017
Non-randomised, open-label dose escalation. n = 5 per arm (20M, 100M, 200M cells), single intravenous infusion [3].
- No treatment-emergent serious adverse events at 1 month; no significant donor-specific immune reactions over 6 months
- 6-minute walk distance increased in all treatment groups at 3 months (p = .02) and 6 months (p = .001); TNF-α decreased at 6 months
- ⚠️ One death at 258 days post-infusion, in the 200-million group
⚠️ Five patients per arm, no control group. This establishes feasibility and little else, and it does not demonstrate a dose-response — all groups improved.
Phase 2 — Tompkins 2017 (CRATUS)
Randomised, double-blinded, placebo-controlled, dose-finding. n = 30, mean age 75.5 ± 7.3, all with frailty. 100M or 200M cells versus placebo [4].
- Primary endpoint was safety: no therapy-related serious adverse events at 1 month
- 6-minute walk test, short physical performance battery and FEV₁ improved in the 100-million group (p = .01) — and NOT in the 200-million or placebo groups
- Female sexual quality-of-life score improved in the 100M group (p = .03)
- Serum TNF-α decreased in the 100M group (p = .03)
⚠️ Read the dose result carefully, because it runs against intuition and against most marketing: the higher dose did not outperform the lower one on physical performance. The authors conclude the cells were safe, with improvements warranting larger trials to establish efficacy.
Not measured in either trial: grip strength. Not reported: IL-6.
Phase 2b — Ruiz 2026 ⭐
The largest and most recent trial in this indication, and the strongest evidence on this page. Randomised, dose-finding, placebo-controlled, N = 148 ambulatory people with frailty (NCT03169231) [15].
Primary endpoint — 6-minute walk test versus placebo:
+63.4 m (95% CI 17.1–109.6; p = 0.0077) at month 9
+41.3 m (95% CI −2.4 – 84.9; p = 0.0635) at month 6 — not statistically significant
- Increases described by the authors as "clinically meaningful, dose- and time-dependent"
- 6MWT gains correlated with PROMIS Physical Function score
- Higher doses associated with decreases in soluble TIE2, proposed as a candidate response biomarker
⚠️ Both timepoints matter. The 6-month result did not reach significance; the 9-month one did. Quoting only the 9-month figure tells half the story.
⚖️ This trial does demonstrate dose-dependence, which the 2017 studies did not. Both facts belong here: dose-dependence is now supported, and the earlier evidence had 100M outperforming 200M.
Umbilical cord cells specifically — Zhu 2024
Randomised, double-blind, placebo-controlled trial of intravenous UC-MSCs — the cell source used in most commercial offerings [16].
- SF-36 physical component score improved from the first post-treatment visit and was sustained (p = 0.042 versus placebo)
- EQ-VAS improved at 2 months (p = 0.023) through 6 months (p = 0.002)
- Timed up-and-go showed a significant group difference over 6 months
The Disease-Severity Question, Stated Honestly
You will see it claimed that stem cell therapy works better in healthier people, and that this makes it a good preventive purchase.
⚠️ No trial supports that claim. There is no study comparing treatment response between healthier and less healthy recipients. Every trial above enrolled frail patients and compared them against placebo — not against sicker patients.
What is genuinely supported is narrower, and it is about disease stage rather than general health. In knee osteoarthritis, where the question has actually been studied, less advanced structural disease predicts better response than end-stage disease, and patient phenotype and OA severity are identified as parameters influencing effectiveness. That is a real finding, in one indication, on radiographic grading.
⚠️ "Earlier-stage disease responds better than end-stage disease" is not the same statement as "healthy people respond better than sick people." Everyone in the supporting evidence has the disease. The second is not a stronger version of the first — it is a different claim, and it has not been tested.
It also carries a cost. A claim that outcomes depend on how healthy you were beforehand supplies a ready explanation for every disappointing result and locates it in the patient. For the same reason, we do not tell people that being overweight or diabetic will make the treatment work less well for them: that is an assertion nobody has tested, and it converts an untested claim into a judgement about the person in front of you.
Safety
This section comes before the case for treatment, because you are, by hypothesis, well. Someone with disabling knee pain is weighing a known problem against an unknown risk. A well 55-year-old is weighing nothing against an unknown risk, and the threshold should be higher, not lower.
What the safety evidence shows. A systematic review and meta-analysis of MSC clinical trials (SafeCell) found no association between MSC administration and acute infusional toxicity, organ system complications, infection, death or malignancy, with transient fever the one signal identified [17]. Across the frailty trials, no therapy-related serious adverse events occurred at one month [3][4].
Reported effects are typically mild and short-lived: transient fever, fatigue, headache, infusion-site reactions.
What is not established:
- ⚠️ Long-term safety in healthy people has never been studied, because healthy people have never been enrolled
- Repeat-dosing safety is not well characterised, and because MSCs are immune evasive rather than immune privileged, sensitisation across repeated allogeneic exposures is a real question [13]
- One death occurred at 258 days in the 200-million arm of the phase 1 study [3]. It was not attributed to treatment, and with n = 5 per arm no inference is possible either way — which is exactly why it should be stated rather than omitted
Not appropriate for: active malignancy · active infection · pregnancy · significant immunosuppression · anyone who has not discussed this with their own physician.
What This Means If You Are Well
Honestly: the evidence does not cover you.
Every result on this page comes from people with diagnosed frailty — mean age 75, impaired walking, measurable functional deficits. The improvements are real, placebo-controlled, and measured in exactly the population that had something to improve.
There is no trial of MSC therapy in healthy adults for prevention, longevity or biological-age reversal. Extending these results to a well 55-year-old is an extrapolation, and we would rather call it that than dress it up.
What is well established for healthy aging, and outperforms anything on this page: regular exercise including resistance training, sleep, not smoking, and management of blood pressure, lipids and glucose. We will say so even though it is not what we sell.
Frequently Asked Questions
Is this FDA-approved?
No. MSC therapy is not FDA-approved for aging, frailty or longevity, and is available in the United States only within clinical trials. Products offered elsewhere operate under different regulatory frameworks; availability is not approval.
Does it reverse biological age?
There is no evidence that it does. No trial has shown MSC therapy altering an epigenetic clock or any validated measure of biological age in humans. Anyone claiming otherwise should be asked for the trial.
Donor cells or my own?
Autologous cells carry your own age — proliferative capacity and secretory profile decline with donor age. Allogeneic cord-derived cells avoid that and need no culture wait. ⚠️ That is a laboratory rationale, not a demonstrated clinical advantage: a head-to-head comparison in cardiomyopathy found allogeneic cells performed at least as well as autologous [14], but no head-to-head trial exists in aging or frailty.
How long do effects last?
Unknown beyond the trial windows, which ran to 6 or 9 months. Claims of "12–24 months" durability have no trial behind them.
Will I feel it quickly?
The trials measured function at 3, 6 and 9 months. In the largest trial the 6-month result did not reach statistical significance and the 9-month one did. Timelines promising effects within weeks are not derived from this evidence.
Can this replace exercise and the rest of it?
No, and nothing in the evidence suggests it could. The trials added MSC infusion on top of participants' existing care.
The Bottom Line
The biology of aging is genuinely well described, and MSC therapy for frailty has produced a real, placebo-controlled, clinically meaningful result: +63.4 m on the 6-minute walk test at nine months, in 148 people who were frail [15].
That is a good result, and it is not a longevity treatment. It was achieved in patients with a diagnosed syndrome, measured on a walking test, over nine months. Whether it does anything for a healthy person has not been studied.
If you are considering this while well, the honest position is that you would be buying an extrapolation with a reasonable safety record and no efficacy evidence in your situation — and we would rather you knew that.